What is Passage Bio, Inc. (PASG)?

Passage Bio, Inc. (PASG) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of PASG?

The current price of PASG is $3.52. Prices are updated in real time on Stocks360.

What is PASG's price-to-earnings (PE) ratio?

PASG's trailing twelve-month PE ratio is -0.31, based on current price and earnings per share data available on Stocks360.

What is PASG's market capitalization?

PASG's market capitalization is $11,326,691.00, placing it in the small-cap tier.

Passage Bio, Inc. (PASG)

Stock analysis · NASDAQ · Healthcare · Biotechnology

$3.52

Market Cap

$11.33M

PE (TTM)

-0.31

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

1.39

Day Range

$3.44 – $3.83

52-wk Range

$3.29 – $20.00

Avg Volume

N/A

Volume

16.69K

Passage Bio, Inc. (PASG) is a publicly traded company in the Healthcare sector. Latest price: $3.52. Market cap $11.33M. Trailing PE -0.31. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-30 · $7.40 2026-10-29 · $3.52 (-52.43%)

Earnings

Most Recent

Aug 10, 2026

EPS $-2.44 vs est. $-2.27

Missed by $0.17

Next Earnings

Nov 9, 2026

EPS estimate $-2.43

Proprietary Signals

Signal snapshot temporarily unavailable.

About Passage Bio, Inc.

Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues. Another key program, PBFT02, employs an AAV1 capsid to introduce a functional granulin (GRN) gene, encoding progranulin (PGRN), to the brain as a treatment for FTD-GRN. Additionally, PBKR03 is under development for infantile Krabbe disease, leveraging a proprietary AAVhu68 capsid to deliver a functional GALC gene, responsible for producing the hydrolytic enzyme galactosylceramidase, to the brain and surrounding tissues. The company's portfolio also features PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis, and PBCM06 for Charcot-Marie-Tooth Type 2A. Passage Bio maintains a significant research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, alongside a development services and clinical supply agreement…

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.31×
P/S (TTM)	0.00×
P/B	2.53×
P/FCF (TTM)	-0.34×
EV / EBITDA	0.39×
EV / Sales	0.00×
Earnings Yield	-319.72%
Free Cash Flow Yield	-295.76%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$12.83M
Net Income (TTM)	-$36.21M
Free Cash Flow (TTM)	-$33.50M
Net Debt	-$24.16M
Working Capital	$4.46M
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Return on Equity	-218.59%
Return on Invested Capital	-889.92%